A biotech sector fund with headquarters in China is equipped with state-of-the-art instruments housed by modern laboratories in an artistically designed building. The firm works with top ten largest global pharmaceutical companies and small to medium sized US and Europe-based businesses in studies of gene-to-structure, in vitro and in vivo assays, target ID, ADME, animal models, and more.

The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 10-12 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Medical Devices Healthcare IT companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in the USA focuses on early-stage diagnostics, life science research tools, and biotech-related companies. The firm’s target initial investment size is $500K-$1M, and the firm has made one investment so far. The firm prefers to act as the co-investor with other types of investors such as strategic partners. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early-stage diagnostics, life science research tools, and biotech-related companies. The firm will invest in a limited number of therapeutic opportunities. The firm also has interests in other technology fields. The firm is opportunistic in terms of subsectors and indications. The firm will consider investing in companies that have strong intellectual property protection and provide barriers to competitive entry. The firm also seeks companies with potential large addressable markets, which typically have the potential to generate at least $100M of annual revenues.

The firm seeks a reliable and experienced management team that can bring the concept to market. The firm may take a board seat in applicable cases. The firm aims fundraising CEOs that are driven to deliver exceptional investment returns to both investors and management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage investor in emerging life science technologies with offices in the USA seeks to invest in promising early-stage assets, create a company around each asset and then directly manage the startup. The firm’s investment sizes vary from $1-40 million. Investments are made at the seed stage or in Series A venture rounds; the firm prefers to be the first institutional investor. The firm has invested in assets sourced throughout the USA and has evaluated investment opportunities globally.

The firm primarily invests in therapeutics-focused opportunities. The firm is technologically agnostic and is open to any indication area, with a particular interest in CNS, digital health, oncology and immunology. The firm is interested in preclinical-stage assets and will consider investing in assets as early as the discovery stage.

The firm is open to working with both academic projects and entrepreneurs, and also deprioritized pharma assets. The firm generally does not make new investments into companies any later than the Series A stage. The firm supplies management and technical expertise to develop an asset if the company does not have a full management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare focused venture capital firm based in China, with offices in Shanghai and Beijing, makes venture investments in early & growth stage companies and PIPE deals. The firm is flexible regarding the investment size; the firm can invest anywhere from several hundred thousand dollars up to USD 10 million or more. The firm generally invests in global companies with current investments mostly in US and China. The firm is actively seeking new investment opportunities.

The firm invests opportunistically in the life sciences. The firm is interested in biopharmaceuticals, medical devices, diagnostics, and mobile/digital health. Within therapeutics, the firm is most interested in oncology and neurology. The firm considers all molecules and biologics, including biosimilars and reformulated drugs. In terms of stage of development, the firm looks for products in early to late stages of clinical trials. The firm generally looks for devices in later stages of development or close to market.

The firm invests in both private and public companies, and has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital firm with a new second fund closed in early 2020, invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Western Europe currently manages three funds, the newest of which closed in 2020 and focuses on investments in Europe-based therapeutics and medical innovation. The firm invests in Europe and North America, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private wealth investment vehicle based in Western Europe is looking to invest in therapeutics companies as well as companies developing digital therapeutics or therapeutic-enabling technologies. The firm is primarily interested in early stage, pre-clinical breakthrough technologies and, especially for digital-based companies, capital efficient business models. While the firm has invested primarily within Western Europe up until now, The firm is willing to consider companies in other geographies if they find the technology compelling. For a first investment, the firm invests, on average, 2M, but can invest smaller or larger amounts, depending on the company and its needs.

The firm is looking for companies in the broader therapeutics space. The firm is interested not only in more traditional therapeutics technologies, but also in digital therapeutics and digital therapeutic-enabling technologies, drug development platforms, including digital and genomics-based drug development technologies, and in cell and gene therapy manufacturing technologies. The firm has historically invested primarily in technologies relating to oncology, but will consider any indication.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.